Silo Pharma, Inc.
Silo Pharma is a developmental-stage biopharmaceutical and cryptocurrency company developing conventional drugs and psychedelic formulations for conditions including PTSD, anxiety disorders, fibromyalgia, chronic pain, Alzheimer’s disease and multiple sclerosis. Its four therapeutic candidates are SPC-15, an intranasal treatment for PTSD and anxiety; SP-26, a ketamine-based time-release implant for fibromyalgia and chronic pain; SPC-14, a candidate for Alzheimer’s disease; and SPU-16, a peptide-based candidate for central nervous system disorders. The company works with universities and researchers to acquire or develop intellectual property and technology rights, and licenses its products and technologies. It also holds Bitcoin, Ethereum, Solana and other digital assets, and participates in staking to earn a share of blockchain rewards. Silo Pharma is headquartered in Sarasota, Florida.
No SEC Form 4 filings for $SILO in the last 30 days.
See all $SILO insider activity →Silo Pharma raised $815,000 in a private placement, issuing 136,005 shares at $1.50 each and pre-funded warrants for 430,661 shares at $1.4999 per warrant. Proceeds will fund working capital and corporate purposes, with the transaction closing on November 6, 2026.
Silo Pharma, Inc. (SILO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On November 5, 2026, Silo Pharma, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain accredited investors (“the “Purchasers”) for the issuance and sale in a private place
Silo Pharma, Inc. (SILO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 13, 2026, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Larry King (the “Seller”). Pursuant to the Agreement, the Seller agreed to sell, and the Company agreed to
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SILO (Silo Pharma, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent SILO coverage spans corporate actions, technology and market movers.
The fresh capital infusion may modestly support liquidity and operations, potentially limiting dilution concerns.
The cash infusion provides working capital but the small size limits market impact.
The share issuance dilutes existing shareholders and introduces a lock‑up, likely weighing on the stock.
The company will issue a warrant and shares, potentially diluting existing shareholders and creating future upside if exercised.
The new NVIDIA model support and Hermes runtime broaden QwikAgents' AI offering, potentially attracting more customers and modestly boosting the stock.
AlphAI scores every news story that mentions SILO with an AI model for sentiment and relevance, and aggregates insider trades from Silo Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Silo Pharma raised $815,000 in a private placement, issuing 136,005 shares at $1.50 each and pre-funded warrants for 430,661 shares at $1.4999 per warrant. Proceeds will fund working capital and corporate purposes, with the transaction closing on November 6, 2026.
Silo Pharma, Inc. (SILO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On November 5, 2026, Silo Pharma, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain accredited investors (“the “Purchasers”) for the issuance and sale in a private place
Silo Pharma, Inc. (SILO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 13, 2026, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Larry King (the “Seller”). Pursuant to the Agreement, the Seller agreed to sell, and the Company agreed to
Silo Pharma, Inc. (SILO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 1, 2026, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Norsight Consulting Inc., an Arkansas corporation (the “Seller”). Pursuant to the Agreement, the Seller agre
Silo Pharma (SILO) announced that its subsidiary QwikAgents has added support for NVIDIA API keys and Hermes runtime. This allows customers to access NVIDIA's Nemotron models and choose between two runtimes. The company aims to provide flexibility in AI model and runtime selection.
IM Cannabis (IMCC) surged 245% with no clear catalyst, trading between $2.97 and $8.65. XORTX (XRTX) rose 12% on plans for a 2026 FDA application. Silo Pharma (SILO) gained 6.73% after a U.S. patent allowance. Biofrontera (BFRI) increased 5.65% despite no new news, following an FDA approval for Ameluz.
Silo Pharma (SILO) received a U.S. patent allowance for SPC-15, its PTSD treatment. The patent covers compositions and methods for preventing stress-induced behavioral responses. The company's stock closed at $1.72, down 2.27%, and is trading at $1.65 in pre-market.
Silo Pharma, Inc. (SILO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 18, 2026, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Parkview Consulting LLC (the “Seller”). Pursuant to the Agreement, the Seller agreed to sell, and the Compan
Silo Pharma, Inc. (SILO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On August 14, 2026, shareholders of Silo Pharma, Inc. (the “Company”) approved an increase to the number of authorized shares of the Company’s common stock, par value $0.0001 (“Common Stock”) from
Indonesia Stock Exchange (IDX) expanded its High Shareholding Concentration (HSC) list to 51 stocks, adding names including DCII, BYAN, and MORA. The HSC label highlights concentrated ownership and potential liquidity and price sensitivity risks. IDX cited updated methodology and noted regulators are assessing liquidity quality ahead of MSCI review in Nov 2026.
